The company that made surgical expertise travel by screen ran out of money. Its technology found a second life inside a handheld robotics company that is trying to make a difficult first step in care easier to repeat.
VYRSA built a three-product answer to a stubborn source of back pain, won FDA clearance for a stranger kind of implant, and sold to Nevro before its third birthday. The playbook is compact: license hard science, simplify the procedure, and let a bigger sales force carry it.